← Back to Treatments
🏅 FDA Orphan Designation

Jelmyto

mitomycin

Manufacturer: UroGen Pharma, Ltd.

Indicated for:
Upper tract urothelial carcinomaOrphan

FDA-Approved Indications (1)

JELMYTO� is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC)

Indications & Usage

1 INDICATIONS AND USAGE JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). ( 1 )

💙 Support Programs

View all →
Jelmyto
UroGen Pharma, Ltd.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.